The US Food and Drug Administration (USFDA) advisory panel has unanimously recommended that the agency approves the first gene treatment for leukemia. The committee recommended that the FDA take the necessary measures to approve the drug, which has been clinically tested. In the case the FDA approves the launch of the drug, called Tisagenlecleucel (CTL019), it will be the first ever leukemia drug introduced on market. The drug supposedly works on making gene changes to enhance the patient’s natural immune system and improve its ability to control disease. Each patient would have a copy of the drug suiting their body, their cells used in the manufacturing of their own drug.

Source: Egypt Independent July 13, 2017 12:00 UTC